Staging of chronic hyperplastic rhinosinusitis: treatment strategies.
In 1990 we reported an initial prospective study of 100 patients using a four-stage system for classification of chronic rhinosinusitis. Between January 1988 and July 1992, we used this system in staging an additional 1814 patients, on whom 2980 intranasal sphenoethmoidectomies were performed. In this staging system a protocol trial of medication was given for 2 weeks, followed by axial and coronal computed tomography. Medication consisted of a second-generation cephalosporin antibiotic, usually cefuroxime; a 4-day burst of intraoral steroids, usually prednisone; and an antihistamine decongestant if not contraindicated. The stages of chronic hyperplastic rhinosinusitis included the stages described in the 1990 report (i.e., stage I, single-focus disease; stage II, discontiguous disease throughout the ethmoid labyrinth; stage III, diffuse disease responsive to medication; and stage IV, diffuse disease unresponsive to or poorly responsive to medication). The results of this study have shown that the computed tomography staging system based on computed tomography extent of disease after medical therapy is a simple, easily remembered, and very effective modality for the classification of chronic sinusitis. This system provides a rationale for discussing and planning surgery with patients and physicians and is a convenient reference for the reporting of end results. More importantly, a linear relationship between disease stage and outcomes is demonstrated. This statistically highly significant feature of the staging system provides a firm basis for the production of outcomes after various treatment strategies, particularly ethmoidectomy and the treatment of sinusitis.
Friedman
W H
WH
Park Central Institute, St. Louis, MO 63139.
Katsantonis
G P
GP
Bumpous
J M
JM
D001507:Beclomethasone / Q000008:administration & dosage / Q000627:therapeutic use; D002444:Cefuroxime / Q000008:administration & dosage / Q000627:therapeutic use; D002908:Chronic Disease; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D005005:Ethmoid Sinus / Q000601:surgery; D015521:Ethmoid Sinusitis / Q000145:classification / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery; D005500:Follow-Up Studies; D006140:Guaifenesin / Q000008:administration & dosage / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006965:Hyperplasia; D014663:Nasal Decongestants / Q000627:therapeutic use; D010347:Patient Care Planning; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011446:Prospective Studies; D012008:Recurrence; D012220:Rhinitis / Q000145:classification* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery; D012852:Sinusitis / Q000145:classification* / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery; D013101:Sphenoid Sinus / Q000601:surgery; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D006634:Histamine H1 Antagonists; D014663:Nasal Decongestants; D006140:Guaifenesin; D001507:Beclomethasone; D002444:Cefuroxime; D011241:Prednisone